The relapse rate of multiple sclerosis (MS) is typically reduced during late pregnancy but increases in the postpartum period. The reasons for the increased postpartum activity are not entirely clear, but factors such as the abrupt decrease in oestrogen levels immediately after the delivery and the loss of the immunosuppressive state of pregnancy are likely of importance. There is a general view that MS does not affect the course or outcome of pregnancy.
PolmanCH, ReingoldSC, EdanG, Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol2005;58:840–6
3.
OrtonSM, HerreraBM, YeeIM, Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol2006;5:932–6
4.
Korn-LubetzkiI, KahanaE, CooperG, AbramskyO. Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol1984;16:229–31
5.
MillarJH, AllisonRS, CheesemanEA, MerrettJD. Pregnancy as a factor influencing relapse in disseminated sclerosis. Brain1959;82:417–26
6.
GhezziA, CaputoD. Pregnancy: a factor influencing the course of multiple sclerosis?Eur Neurol1981;20:115–7
7.
FrithJA, McLeodJG. Pregnancy and multiple sclerosis. J Neurol Neurosurg Psychiatry1988;51:495–8
8.
ConfavreuxC, HutchinsonM, HoursMM, Cortinovis-TourniaireP, MoreauT. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med1998;339:285–91
9.
VukusicS, HutchinsonM, HoursM, Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain2004;127:1353–60
10.
van WalderveenMA, TasMW, BarkhofF, Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis. Neurology1994;44:327–9
11.
PaavilainenT, KurkiT, ParkkolaR, Magnetic resonance imaging of the brain used to detect early post-partum activation of multiple sclerosis. Eur J Neurol2007;14:1216–21
12.
KaajaR, GreerI. Manifestations of chronic disease during pregnancy. JAMA2005;294:2751–7
13.
WegmannTG, LinH, GuilbertL, MosmannTR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?Immunol Today1993;14:353–6
14.
Sanchez-RamonS, NavarroAJ, AristimunoC, Pregnancy induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity. Immunol Lett2005;96:195–201
15.
SarasteM, RyynanenJ, AlanenA, Cerebrospinal fluid findings in multiple sclerosis patients before, during and after pregnancy. J Neurol Neurosurg Psychiatry2006;17:1195–6
16.
GilmoreW, WeinerLP, CorrealeJ. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol1997;158:446–51
17.
PauklinS, SernandezIV, BachmannG, RamiroAR, Petersen-MahrtSK. Estrogen directly activates AID transcription and function. J Exp Med2009;206:99–111
PolanczykM, ZamoraA, SubramanianS, The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol2003;163:1599–605
20.
SicotteNL, LivaSM, KlutchR, Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol2002;52:421–8
21.
JalkanenA, AlanenA, AirasL, the Finnish Multiple Sclerosis and Pregnancy Study Group. Pregnancy outcome in women with multiple sclerosis – results from a prospective nationwide study in Finland. Mult Scler2010;16:950–5
22.
MuellerBA, ZhangJ, CritchlowCW. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol2002;186:446–52
23.
DahlJ, MyhrKM, DaltveitAK, HoffJM, GilhusNE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology2005;65: 1961–3
24.
BamfordC, SibleyW, LagunaJ. Anesthesia in multiple sclerosis. Can J Neurol Sci1978;5:41–4
25.
De Las HerasV, De AndresC, TellezN, TintoreM. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. Mult Scler2007;13:981–4
26.
BoskovicR, WideR, WolpinJ, BauerDJ, KorenG. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology2005;65:807–11
27.
Sandberg-WollheimM, FrankD, GoodwinTM, Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology2005
28.
PattiF, CavallaroT, Lo FermoS, Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?J Neurol2008;255:1250–3
29.
AmatoMP, PortaccioE, GhezziA, Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology2010;75:1794–802
30.
Sandberg-WollheimM, AlteriE, Stam MoragaM, KornmannG. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a. Therapy Mult Scler2011;17:423–30
31.
SalminenHJ, LeggettH, BoggildM. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol2010;257:2020–3
32.
GisbertJP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis2010;16:881–95
33.
HoevenarenIA, de VriesLC, RijndersRJ, LotgeringFK. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand2011;123:430–3
34.
De SantisM, StrafaceG, CavaliereAF, RosatiP, BatocchiAP, CarusoA. The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology2007;28:696–7
35.
HellwigK, BruneN, HaghikiaA, Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand2008;118:24–8
36.
AirasL, JalkanenA, AlanenA, PirttilaT, MarttilaR. Breastfeeding, postpartum and pre-pregnancy disease activity in multiple sclerosis. Neurology2010;75:474–6
37.
OddyWH. A review of the effects of breastfeeding on respiratory infections, atopy, and childhood asthma. J Asthma2004;41:605–21
38.
Langer-GouldA, HuangSM, GuptaR, Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol2009;66:958–63
39.
FazekasF, DeisenhammerF, Strasser-FuchsS, NahlerG, MamoliB. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet1997;349:589–93
40.
FazekasF, LublinFD, LiD, Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology2008;71:265–71
41.
AchironA, KishnerI, DolevM, Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol2004;251:1133–7
